A low level of CD16pos monocytes in SARS-CoV-2 infected patients is a marker of severity

Severe forms of coronavirus disease 2019 (COVID-19) are characterized by an excessive production of inflammatory cytokines. Activated monocytes secrete high levels of cytokines. Human monocytes are divided into three major populations: conventional (CD14posCD16neg), non-classical (CD14dimCD16pos), a...

Full description

Saved in:
Bibliographic Details
Published inClinical chemistry and laboratory medicine Vol. 59; no. 7; pp. 1315 - 1322
Main Authors Vasse, Marc, Zuber, Benjamin, Goubeau, Laurie, Ballester, Marie-Christine, Roumier, Mathilde, Delcominette, Frédérique, Habarou, Florence, Jolly, Emilie, Ackermann, Felix, Cerf, Charles, Farfour, Eric, Pascreau, Tiffany
Format Journal Article
LanguageEnglish
Published Berlin De Gruyter 25.06.2021
Walter De Gruyter & Company
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Severe forms of coronavirus disease 2019 (COVID-19) are characterized by an excessive production of inflammatory cytokines. Activated monocytes secrete high levels of cytokines. Human monocytes are divided into three major populations: conventional (CD14posCD16neg), non-classical (CD14dimCD16pos), and intermediate (CD14posCD16pos) monocytes. The aim of this study was to analyze whether the distribution of conventional (CD16neg) and CD16pos monocytes is different in patients with COVID-19 and whether the variations could be predictive of the outcome of the disease.We performed a prospective study on 390 consecutive patients referred to the Emergency Unit, with a proven diagnosis of SARS-CoV 2 infection by RT-PCR. Using the CytoDiff™ reagent, an automated routine leukocyte differential, we quantified CD16neg and CD16pos monocytes.In the entire population, median CD16neg and CD16pos monocyte levels (0.398 and 0.054×109/L, respectively) were in the normal range [(0.3–0.7×109/L) and (0.015–0.065×109/L), respectively], but the 35 patients in the intensive care unit (ICU) had a significantly (p<0.001) lower CD16pos monocyte count (0.018 × 109/L) in comparison to the 70 patients who were discharged (0.064 × 109/L) or were hospitalized in conventional units (0.058 × 109/L). By ROC curve analysis, the ratio [absolute neutrophil count/CD16pos monocyte count] was highly discriminant to identify patients requiring ICU hospitalization: with a cut-off 193.1, the sensitivity and the specificity were 74.3 and 81.8%, respectively (area under the curve=0.817).Quantification of CD16pos monocytes and the ratio [absolute neutrophil count/CD16pos monocyte count] could constitute a marker of the severity of disease in COVID-19 patients.
AbstractList Severe forms of coronavirus disease 2019 (COVID-19) are characterized by an excessive production of inflammatory cytokines. Activated monocytes secrete high levels of cytokines. Human monocytes are divided into three major populations: conventional (CD14posCD16neg), non-classical (CD14dimCD16pos), and intermediate (CD14posCD16pos) monocytes. The aim of this study was to analyze whether the distribution of conventional (CD16neg) and CD16pos monocytes is different in patients with COVID-19 and whether the variations could be predictive of the outcome of the disease.We performed a prospective study on 390 consecutive patients referred to the Emergency Unit, with a proven diagnosis of SARS-CoV 2 infection by RT-PCR. Using the CytoDiff™ reagent, an automated routine leukocyte differential, we quantified CD16neg and CD16pos monocytes.In the entire population, median CD16neg and CD16pos monocyte levels (0.398 and 0.054×109/L, respectively) were in the normal range [(0.3–0.7×109/L) and (0.015–0.065×109/L), respectively], but the 35 patients in the intensive care unit (ICU) had a significantly (p<0.001) lower CD16pos monocyte count (0.018 × 109/L) in comparison to the 70 patients who were discharged (0.064 × 109/L) or were hospitalized in conventional units (0.058 × 109/L). By ROC curve analysis, the ratio [absolute neutrophil count/CD16pos monocyte count] was highly discriminant to identify patients requiring ICU hospitalization: with a cut-off 193.1, the sensitivity and the specificity were 74.3 and 81.8%, respectively (area under the curve=0.817).Quantification of CD16pos monocytes and the ratio [absolute neutrophil count/CD16pos monocyte count] could constitute a marker of the severity of disease in COVID-19 patients.
Severe forms of coronavirus disease 2019 (COVID-19) are characterized by an excessive production of inflammatory cytokines. Activated monocytes secrete high levels of cytokines. Human monocytes are divided into three major populations: conventional (CD14posCD16neg), non-classical (CD14dimCD16pos), and intermediate (CD14posCD16pos) monocytes. The aim of this study was to analyze whether the distribution of conventional (CD16neg) and CD16pos monocytes is different in patients with COVID-19 and whether the variations could be predictive of the outcome of the disease.OBJECTIVESSevere forms of coronavirus disease 2019 (COVID-19) are characterized by an excessive production of inflammatory cytokines. Activated monocytes secrete high levels of cytokines. Human monocytes are divided into three major populations: conventional (CD14posCD16neg), non-classical (CD14dimCD16pos), and intermediate (CD14posCD16pos) monocytes. The aim of this study was to analyze whether the distribution of conventional (CD16neg) and CD16pos monocytes is different in patients with COVID-19 and whether the variations could be predictive of the outcome of the disease.We performed a prospective study on 390 consecutive patients referred to the Emergency Unit, with a proven diagnosis of SARS-CoV 2 infection by RT-PCR. Using the CytoDiff™ reagent, an automated routine leukocyte differential, we quantified CD16neg and CD16pos monocytes.METHODSWe performed a prospective study on 390 consecutive patients referred to the Emergency Unit, with a proven diagnosis of SARS-CoV 2 infection by RT-PCR. Using the CytoDiff™ reagent, an automated routine leukocyte differential, we quantified CD16neg and CD16pos monocytes.In the entire population, median CD16neg and CD16pos monocyte levels (0.398 and 0.054×109/L, respectively) were in the normal range [(0.3-0.7×109/L) and (0.015-0.065×109/L), respectively], but the 35 patients in the intensive care unit (ICU) had a significantly (p<0.001) lower CD16pos monocyte count (0.018 × 109/L) in comparison to the 70 patients who were discharged (0.064 × 109/L) or were hospitalized in conventional units (0.058 × 109/L). By ROC curve analysis, the ratio [absolute neutrophil count/CD16pos monocyte count] was highly discriminant to identify patients requiring ICU hospitalization: with a cut-off 193.1, the sensitivity and the specificity were 74.3 and 81.8%, respectively (area under the curve=0.817).RESULTSIn the entire population, median CD16neg and CD16pos monocyte levels (0.398 and 0.054×109/L, respectively) were in the normal range [(0.3-0.7×109/L) and (0.015-0.065×109/L), respectively], but the 35 patients in the intensive care unit (ICU) had a significantly (p<0.001) lower CD16pos monocyte count (0.018 × 109/L) in comparison to the 70 patients who were discharged (0.064 × 109/L) or were hospitalized in conventional units (0.058 × 109/L). By ROC curve analysis, the ratio [absolute neutrophil count/CD16pos monocyte count] was highly discriminant to identify patients requiring ICU hospitalization: with a cut-off 193.1, the sensitivity and the specificity were 74.3 and 81.8%, respectively (area under the curve=0.817).Quantification of CD16pos monocytes and the ratio [absolute neutrophil count/CD16pos monocyte count] could constitute a marker of the severity of disease in COVID-19 patients.CONCLUSIONSQuantification of CD16pos monocytes and the ratio [absolute neutrophil count/CD16pos monocyte count] could constitute a marker of the severity of disease in COVID-19 patients.
Author Goubeau, Laurie
Cerf, Charles
Habarou, Florence
Ackermann, Felix
Zuber, Benjamin
Delcominette, Frédérique
Roumier, Mathilde
Farfour, Eric
Vasse, Marc
Jolly, Emilie
Pascreau, Tiffany
Ballester, Marie-Christine
Author_xml – sequence: 1
  givenname: Marc
  orcidid: 0000-0002-8784-7209
  surname: Vasse
  fullname: Vasse, Marc
  email: m.vasse@hopital-foch.org
  organization: UMRS-1176, Le Kremlin-Bicêtre, France
– sequence: 2
  givenname: Benjamin
  surname: Zuber
  fullname: Zuber, Benjamin
  organization: Intensive Care Unit, Foch Hospital, Suresnes, France
– sequence: 3
  givenname: Laurie
  surname: Goubeau
  fullname: Goubeau, Laurie
  organization: Biology Department, Foch Hospital, Suresnes, France
– sequence: 4
  givenname: Marie-Christine
  surname: Ballester
  fullname: Ballester, Marie-Christine
  organization: Emergency Unit, Foch Hospital, Suresnes, France
– sequence: 5
  givenname: Mathilde
  surname: Roumier
  fullname: Roumier, Mathilde
  organization: Internal Medicine Department, Foch Hospital, Suresnes, France
– sequence: 6
  givenname: Frédérique
  surname: Delcominette
  fullname: Delcominette, Frédérique
  organization: Biology Department, Foch Hospital, Suresnes, France
– sequence: 7
  givenname: Florence
  surname: Habarou
  fullname: Habarou, Florence
  organization: Biology Department, Foch Hospital, Suresnes, France
– sequence: 8
  givenname: Emilie
  surname: Jolly
  fullname: Jolly, Emilie
  organization: Biology Department, Foch Hospital, Suresnes, France
– sequence: 9
  givenname: Felix
  surname: Ackermann
  fullname: Ackermann, Felix
  organization: Internal Medicine Department, Foch Hospital, Suresnes, France
– sequence: 10
  givenname: Charles
  surname: Cerf
  fullname: Cerf, Charles
  organization: Intensive Care Unit, Foch Hospital, Suresnes, France
– sequence: 11
  givenname: Eric
  orcidid: 0000-0003-3243-8018
  surname: Farfour
  fullname: Farfour, Eric
  organization: Biology Department, Foch Hospital, Suresnes, France
– sequence: 12
  givenname: Tiffany
  surname: Pascreau
  fullname: Pascreau, Tiffany
  organization: UMRS-1176, Le Kremlin-Bicêtre, France
BookMark eNpdkE1Lw0AQhhepYFu9el7w4mV1Zz_ycfBQ4icUBKviLWySiaQm2ZrdWPrvTawgeHpnmIeX4ZmRSWtbJOQU-AVo0Jd5XjdMcMEZRBwOyBSUDJmSEiY_s2JBIOCIzJxbcw5aq3BK3ha0tlta4xfW1JY0uYZgYx1tbGvznUdHq5auFk8rlthXJoatxNxjQTfGV9j64e6ooY3pPrAbC9zQ1FV-d0wOS1M7PPnNOXm5vXlO7tny8e4hWSzZRijumYjLEjJEDCXXGTfhmKIoszgAU4BAU_A8ioQKELM4M1EmIp4bDVJHEZco5-R837vp7GePzqdN5XKsa9Oi7V0qVAyxAh7yAT37h65t37XDd6nQSoDgKpADdbWntqb22BX43vWDiO4PBp6OwtNReDoKT0fhOg5Bgpbf3G11xA
ContentType Journal Article
Copyright 2021 Walter de Gruyter GmbH, Berlin/Boston
2021 Walter de Gruyter GmbH, Berlin/Boston.
Copyright_xml – notice: 2021 Walter de Gruyter GmbH, Berlin/Boston
– notice: 2021 Walter de Gruyter GmbH, Berlin/Boston.
DBID 7QO
7T7
7TK
7U7
8FD
C1K
FR3
P64
7X8
DOI 10.1515/cclm-2020-1801
DatabaseName Biotechnology Research Abstracts
Industrial and Applied Microbiology Abstracts (Microbiology A)
Neurosciences Abstracts
Toxicology Abstracts
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitle Biotechnology Research Abstracts
Technology Research Database
Toxicology Abstracts
Engineering Research Database
Industrial and Applied Microbiology Abstracts (Microbiology A)
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList Biotechnology Research Abstracts
MEDLINE - Academic
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
EISSN 1437-4331
EndPage 1322
ExternalDocumentID 10_1515_cclm_2020_18015971315
GroupedDBID ---
0R~
0~D
29B
354
36B
4.4
53G
5GY
5RE
AAAEU
AABBZ
AAFPC
AAGVJ
AAILP
AALGR
AAOQK
AAOWA
AAPJK
AAQCX
AARRE
AASQH
AAWFC
AAXCG
ABAOT
ABAQN
ABDRH
ABFKT
ABFQV
ABIQR
ABJNI
ABLJU
ABMIY
ABPLS
ABRDF
ABUVI
ABWLS
ABXMZ
ABYBW
ACDEB
ACEFL
ACGFS
ACIWK
ACPMA
ACPRK
ACUND
ACYCL
ACZBO
ADDWE
ADEQT
ADGQD
ADGYE
ADOZN
AECWL
AEDGQ
AEGVQ
AEICA
AEJTT
AENEX
AEQDQ
AERZL
AEXIE
AFBAA
AFBDD
AFBQV
AFCXV
AFGDO
AFQUK
AFRAH
AFYRI
AGBEV
AHOVO
AHVWV
AHXUK
AIERV
AIWOI
AJATJ
AJHHK
AKXKS
ALMA_UNASSIGNED_HOLDINGS
ALUKF
ALYBR
ASYPN
BAKPI
BBCWN
BCIFA
CGQUA
CS3
DU5
EBS
EMOBN
F5P
HZ~
IY9
KDIRW
N9A
O9-
OBC
OBS
OEB
OES
OHH
P2P
PQQKQ
QD8
RDG
SA.
SLJYH
TEORI
UK5
WTRAM
7QO
7T7
7TK
7U7
8FD
ADNPR
C1K
FR3
P64
7X8
ID FETCH-LOGICAL-p240t-29ff1beee7305b0a773052dfb961ad12ead0c88246eeb9ba8b280ca51358803e3
ISSN 1434-6621
1437-4331
IngestDate Fri Jul 11 11:22:49 EDT 2025
Wed Aug 13 08:58:45 EDT 2025
Thu Jul 10 10:36:56 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 7
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-p240t-29ff1beee7305b0a773052dfb961ad12ead0c88246eeb9ba8b280ca51358803e3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-8784-7209
0000-0003-3243-8018
OpenAccessLink https://www.degruyter.com/document/doi/10.1515/cclm-2020-1801/pdf?licenseType=free
PQID 2542120463
PQPubID 105421
PageCount 08
ParticipantIDs proquest_miscellaneous_2491941070
proquest_journals_2542120463
walterdegruyter_journals_10_1515_cclm_2020_18015971315
PublicationCentury 2000
PublicationDate 2021-06-25
PublicationDateYYYYMMDD 2021-06-25
PublicationDate_xml – month: 06
  year: 2021
  text: 2021-06-25
  day: 25
PublicationDecade 2020
PublicationPlace Berlin
PublicationPlace_xml – name: Berlin
PublicationTitle Clinical chemistry and laboratory medicine
PublicationYear 2021
Publisher De Gruyter
Walter De Gruyter & Company
Publisher_xml – name: De Gruyter
– name: Walter De Gruyter & Company
SSID ssj0015547
Score 2.352024
Snippet Severe forms of coronavirus disease 2019 (COVID-19) are characterized by an excessive production of inflammatory cytokines. Activated monocytes secrete high...
SourceID proquest
walterdegruyter
SourceType Aggregation Database
Publisher
StartPage 1315
SubjectTerms CD16
Coronaviruses
COVID-19
Cytokines
Inflammation
intensive care unit
Leukocytes
Leukocytes (neutrophilic)
Markers
Monocytes
Neutrophils
Polymerase chain reaction
Reagents
Severe acute respiratory syndrome coronavirus 2
Viral diseases
Title A low level of CD16pos monocytes in SARS-CoV-2 infected patients is a marker of severity
URI https://www.degruyter.com/doi/10.1515/cclm-2020-1801
https://www.proquest.com/docview/2542120463
https://www.proquest.com/docview/2491941070
Volume 59
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKJgEvEwwQhYGMxFvl0Ti35jErYxNSeWBb1bfKdhxU1CbTmmgaP47fxjmxnbTVhGAvaZXUTurz5Vx8boR8zGQSqDgWLNdSMOB-wAcFD5jmIY9BPHCe4Yb-5Ft0fhV8nYWzXu_3RtRSXclj9evevJKHUBXOAV0xS_Y_KNtOCifgO9AXjkBhOP4TjdPBsrwdLDHupwmr-OxF1yV2tylKdVc1oVaDi_T7BRuXU8Zt4BVomLaY6hq7mYvBCiN0GmcBSEmNzew2NdaxS51UrjVc42-w4EEP_a57fgr6uLZ5QKrdmK6lAceJLn6K1aLF5FkJV0TtcrQXnZcfu7y4viETNOmZqYTgbmX3KngTU2Xymk3ACQD_pr5zcceG4wZ-wKLIpEkfa3cu7lK5LJu2hcMNHOMNnuv5JiHUym80r--VDWFTRkOp5QpAxNGjbbdRtopw7wjHNmQRjSWYYY7j5zh-juPBHMPbPyL7HMwU4LP76dnJ6bT1Y4Gy1rT3cX_Slg2FiT5tP8iWgXNw24RKZPqHWa0NjefyGTmwpgpNDe6ek54uDsmTsYPBIXk8sZR_QWYpBSjSBoq0zKmFIm2hSBcF7aBIHRSpgyJdrKmgBoo4gYPiS3L15fRyfM5s0w52DcphxXiS557UWoPoCOVQxPjJs1wmkScyjwPnGiow64JIa5lIMZJ8NFQi9PwQRImv_VdkrygL_ZrQoVJ5NoqyaCTzIMqVFFmutZdJ7cdgqId9cuTWbG7fyvWchxjjgHXw-uRDexkWBh1hotBlDb8JEi8JPJB2fRLtrHU3018p_uahA9-Sp92bcUT2qptavwO9tpLvLXj-AF0ho24
linkProvider Walter de Gruyter
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lc9MwEN6BdIZyKVDoECggZriqsWRbto8htARoeqCPyc2jxwoYEruT2NOBX8-qcUIpNzj5IFuW_a33oV1_C_DGmSKxWaa5R6M5aT_Sg1omHGUqMzIPUrqwoT85UePz5OM0nd74FyaUVTr8smh_NCuG1IGrbRs2yjZcA2SBB9bO5gSwDHnJSAy-NvPZXdjKAxNLD7aG798eXmxyCWQwr1usJHHClZKio278e5o_nMydq-t09WYtN6zO0QOw6_Wuik2-H7SNObA_b1E5_t8DPYSdzillw5UUPYI7WO3C9mjdC24X7k26FPxjmA7ZrL5is1BsxGrPRu-EuqyXjMS5tnT3JftWsdPh51M-qi-4ZKtqL3SsY3Cl8SXTbB7KghZhAjLNGDroPYHzo8Oz0Zh37Rn4JbkBDZeF98IgIimJ1EQ6C0fpvCmU0E5IktHIkgOfKERTGJ0bmUdWpyJOSWnEGO9Br6orfAossta7XDmVG58ob412HlE4g3FGIVnah_01MmX3jS1LCm3J7gbGsz683gzTiwkpD11h3dI5SSGKhELcqA_qFqK_ZwqBEIFQBhDKAEIZQKBQS8QiffavF76C7fHZ5Lg8_nDy6Tncl6EYJlJcpvvQaxYtviBvpjEvO3H9Bcez8MI
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB7BVipcChQqFgoYiau7sZM4yXHZdimPVojSqrfIjzFCbJPVJlHV_nrG3ewC5QanHJw4dr7JPDyfZgDeOFMkNss092g0J-1HelDLhKNMZUbmQUoXDvSPjtXhafLhPF2xCZueVunw26K7apcVUkeutl04KFvXGiALPLJ2dkEAy5CXjMRo7vxd2MgTEeUD2Bi_e3twtk4lkL286bCSxAlXSoq-cuPfs_zhY25d3mSr10v5zehMH4BZLXfJNfmx17Vmz17fquT4X_t5CFu9S8rGSxl6BHew2oZ7k1UnuG3YPOoT8I_hfMxm9SWbBaoRqz2b7As1rxtGwlxbennDvlfsZPzlhE_qMy7ZkuuFjvX1W2m8YZpdBFLQIkxAhhlD_7wncDo9-Do55H1zBj4nJ6DlsvBeGEQkFZGaSGfhKp03hRLaCUkSGlly3xOFaAqjcyPzyOpUxCmpjBjjHRhUdYVPgUXWepcrp3LjE-Wt0c4jCmcwziggS4ewuwKm7P-wpqTAlqxuqHc2hNfrYfowIeGhK6w7uicpREFCkUVDULcA_TVTCIMIgzJgUAYMyoABBVoiFumzf33wFWx-3p-Wn94ff3wO92VgwkSKy3QXBu2iwxfkyrTmZS-sPwECHu9p
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+low+level+of+CD16pos+monocytes+in+SARS-CoV-2+infected+patients+is+a+marker+of+severity&rft.jtitle=Clinical+chemistry+and+laboratory+medicine&rft.au=Vasse%2C+Marc&rft.au=Zuber%2C+Benjamin&rft.au=Goubeau%2C+Laurie&rft.au=Ballester%2C+Marie-Christine&rft.date=2021-06-25&rft.pub=De+Gruyter&rft.issn=1434-6621&rft.eissn=1437-4331&rft.volume=59&rft.issue=7&rft.spage=1315&rft.epage=1322&rft_id=info:doi/10.1515%2Fcclm-2020-1801&rft.externalDBID=n%2Fa&rft.externalDocID=10_1515_cclm_2020_18015971315
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1434-6621&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1434-6621&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1434-6621&client=summon